Speakers 2021
ALTER Harvey
USA
-
MEETING WITH THE 2020 NOBEL LAUREATES
Presentation
-
-
HEPATITIS DELTA (chairman)
-
New drugs for HDV
Presentation
-
-
The COVID-19 and liver diseases : lessons learned
Presentation
-
-
Optimal management of cholangiocarcinoma
Presentation
-
-
INTRODUCTION (chairman)
-
LESSONS FROM COVID-19 (chairman)
-
IS ELIMINATION OF HCV BY 2030 REALISTIC (chairman)
-
TAKE HOME MESSAGES (chairman)
Presentation
-
BUGIANESI Elisabetta
Italy
-
Natural history of NASH and HCC
Presentation
-
-
NUC therapy: the role of TAF
Presentation
-
CARDOSO Ana Carolina
Brazil
-
The hepatologist
Presentation
-
-
Non-invasive markers in NAFLD
Presentation
-
-
HCC: ADVANCES IN DIAGNOSIS AND PROGNOSIS (chairman)
Presentation
-
-
HCC: EVOLVING CONCEPTS IN THERAPY (chairman)
Presentation
-
-
Acute-on-chronic liver failure
Presentation
-
DUSHEIKO Geoffrey
UK
-
HBV cure: How and when?
Presentation
-
El Ray Ahmed
Egypt
-
Egypt
Presentation
-
-
HEPATITIS B (chairman)
Presentation
-
FAIVRE Sandrine
France
-
Immunotherapy today
Presentation
-
FLISIAK Robert
Poland
-
Central Europe
Presentation
-
-
TAKE HOME MESSAGES (chairman)
-
IS ELIMINATION OF HCV BY 2030 REALISTIC (chairman)
Presentation
-
-
The surgeon
Presentation
-
-
USA
-
Real world evidence in HCC
-
TAKE HOME MESSAGES (chairman)
Presentation
-
-
Management of hepatorenal syndrome
Presentation
-
-
New algorithm for systemic therapy
Presentation
-
HOUGHTON Michael
USA
-
MEETING WITH THE 2020 NOBEL LAUREATES
Presentation
-
-
Eastern Europe
Presentation
-
-
Asia
Presentation
-
-
The role of DAAs
Presentation
-
LIM Seng Gee
Singapore
-
HEPATITIS B (chairman)
-
Is elimination of HBV realistic ?
Presentation
-
MANNS Michael
Germany
-
NAFLD/NASH: MULTIDISCIPLINARY MANAGEMENT OF A SYSTEMIC DISEASE (chairman)
Presentation
-
-
INTRODUCTION (chairman)
-
INTRODUCTION (chairman)
-
LESSONS FROM COVID-19 (chairman)
-
AWARD PHC 2021 (chairman)
-
MEETING WITH THE 2020 NOBEL LAUREATES
-
CONCLUSION (chairman)
-
INTRODUCTION (chairman)
-
CONCLUSION
-
INTRODUCTION (chairman)
-
CONCLUSION (chairman)
Presentation
-
-
The diabetologist
Presentation
-
-
END STAGE LIVER DISEASE (chairman)
Presentation
-
-
NAFLD/NASH: PHYSIOPATHOLOGY, DIAGNOSIS AND OUTCOME (chairman)
Presentation
-
-
Is Hepatitis Delta underestimated?
Presentation
-
-
The new pathology approach
-
Pathology of NAFLD/NASH revisited
Presentation
-
-
Latin America
Presentation
-
-
Current management of Hepatitis E
Presentation
-
-
NAFLD/NASH: PHYSIOPATHOLOGY, DIAGNOSIS AND OUTCOME (chairman)
-
Physiopathology of NAFLD and NASH
Presentation
-
-
France
Presentation
-
CHUNG Raymond
USA
-
HCC: EVOLVING CONCEPTS IN THERAPY (chairman)
Presentation
-
RICE Charles
USA
-
MEETING WITH THE 2020 NOBEL LAUREATES
Presentation
-
-
HEPATITIS DELTA (chairman)
Presentation
-
Presentation
-
-
Changing indications for liver transplantation
Presentation
-
-
New drugs for NASH
Presentation
-
-
END STAGE LIVER DISEASE (chairman)
Presentation
-
-
Making a sustainable impact on COVID-19
Presentation
-
SERFATY Lawrence
France
-
NAFLD/NASH: MULTIDISCIPLINARY MANAGEMENT OF A SYSTEMIC DISEASE (chairman)
Presentation
-
-
The emerging issue of Hepatitis Delta in Asia
Presentation
-
-
Is encephalopathy under-estimated ?
Presentation
-
-
HCC: ADVANCES IN DIAGNOSIS AND PROGNOSIS (chairman)
-
The digital and imaging
Presentation
-
-
Trans-Arterial Radioembolisation (TARE)
Presentation
-
WEDEMEYER Heiner
Germany
-
How do I treat my patients ?
Presentation
-
ZEUZEM Stefan
Germany
-
Western Europe
Presentation
-
ZOULIM Fabien
France
-
New drugs for HBV cure
Presentation
-
-
Clinical applications of genetics in HCC
Presentation
-
